Abstract
Huntington’s Disease (HD) is a neurodegenerative disorder resulting from an expanded polyglutamine (polyQ) repeat in exon1 of the Huntingtin (Htt) protein. This polyQ expansion causes aggregation of the Htt protein in neuronal cells, which is linked to HD pathogenesis. Recent evidence has shown that Htt aggregation and toxicity are not solely dictated by the polyQ-expanded region but also by sequences flanking the polyQ region, particularly the first N-terminal 17 amino acids of Htt (N17). N17 has been shown to be critical in the Htt aggregation mechanism as well as host many post-translational modifications and interactions with molecular chaperones. Understanding how N17 functions in Htt aggregation and as a general handle for protein quality control will guide design of HD therapeutics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
